RecruitingNCT05997810

Parathyroid Tumor Clonal Status

A Phase 2 Biomarker Study of Parathyroid Tumor Clonal Status in Primary Hyperparathyroidism

Sponsor

Washington University School of Medicine

Enrollment

839 participants

Start Date

Jul 28, 2023

Study Type

OBSERVATIONAL

Conditions

Primary Hyperparathyroidism Parathyroid Tumor

Summary

To define the frequency of monoclonal-X and polyclonal-X tumors in PHPT participants having parathyroidectomy (PTX) and to define the relationship between parathyroid tumor clonal status and multiple gland neoplasia (MGN), we will compare surgical and pathologic outcomes to tumor clonal status in a multicenter cohort of patients having bilateral neck exploration (BNE) and PTX (primary objectives).

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study examines tissue from the parathyroid glands in women who have a condition called primary hyperparathyroidism — an overactive parathyroid gland that causes high calcium levels in the blood. Researchers want to better understand how these tumors develop. **You may be eligible if...** - You are female and at least 18 years old - You have been diagnosed with non-inherited primary hyperparathyroidism, confirmed by blood tests showing high calcium and high PTH (parathyroid hormone) within the past 60 days - You are willing and able to provide informed consent **You may NOT be eligible if...** - You have a history of radiation treatment to the neck or face - You have had a previous parathyroid surgery that was unsuccessful - You have hyperparathyroidism caused by kidney disease or a kidney transplant - You are currently taking a medication called a calcimimetic (such as cinacalcet) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.